Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

167
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
167
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

175
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
175
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

420
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
420
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

320
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
320

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity.

Science (New York, N.Y.)·2026
Same author

Enhancing the culture of mouse primary fibroblasts to study age-dependent effects in skin tissue engineering in vitro.

Cells, tissues, organs·2026
Same author

Driving emerging technology to clinical impact.

Journal of the American Dental Association (1939)·2026
Same author

Implantable living materials autonomously deliver therapeutics using contained engineered bacteria.

Science (New York, N.Y.)·2026
Same author

Feeder-free generation of functional dendritic cells from human pluripotent stem cells.

Journal for immunotherapy of cancer·2026
Same author

Matrix Viscoelasticity Regulates Dendritic Cell Migration and Immune Priming.

Advanced materials (Deerfield Beach, Fla.)·2026

Related Experiment Video

Updated: May 6, 2026

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
08:02

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

12.5K

Macroscale delivery systems for molecular and cellular payloads.

Cathal J Kearney1, David J Mooney

  • 1School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA, and Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts 02115, USA.

Nature Materials
|October 24, 2013
PubMed
Summary
This summary is machine-generated.

Macroscale drug delivery (MDD) devices offer localized treatment with enhanced effectiveness and reduced side effects. This review explores MDD advantages, control mechanisms, material selection, and integration with medical devices and tissue engineering.

More Related Videos

Microscale Vortex-assisted Electroporator for Sequential Molecular Delivery
10:51

Microscale Vortex-assisted Electroporator for Sequential Molecular Delivery

Published on: August 7, 2014

7.8K
Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation
06:57

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation

Published on: August 11, 2018

7.7K

Related Experiment Videos

Last Updated: May 6, 2026

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
08:02

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

12.5K
Microscale Vortex-assisted Electroporator for Sequential Molecular Delivery
10:51

Microscale Vortex-assisted Electroporator for Sequential Molecular Delivery

Published on: August 7, 2014

7.8K
Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation
06:57

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation

Published on: August 11, 2018

7.7K

Area of Science:

  • Biomedical Engineering
  • Materials Science
  • Pharmacology

Background:

  • Macroscale drug delivery (MDD) devices provide localized, controlled release of therapeutics, unlike systemic administration.
  • MDD systems act as depots, increasing drug efficacy, minimizing side effects, and protecting sensitive agents like proteins and cells.

Purpose of the Study:

  • To review the advantages and spatiotemporal control mechanisms of MDD systems.
  • To provide guidelines for selecting carrier materials for MDD devices.
  • To discuss the integration of MDD with medical devices and its application in tissue engineering.

Main Methods:

  • Literature review of macroscale drug delivery technologies.
  • Analysis of spatiotemporal control mechanisms in MDD.
  • Discussion of material selection criteria for drug carriers.
  • Exploration of multifunctional MDD device development.
  • Review of MDD applications in tissue engineering.

Main Results:

  • MDD systems offer significant advantages over systemic drug delivery, including localized action and protection of labile agents.
  • Effective spatiotemporal control is achievable through various MDD mechanisms.
  • Material selection is crucial for optimizing MDD performance.
  • Combining MDD with existing medical devices enhances functionality and tissue integration.
  • MDD technology shows promise in directing cell behavior for tissue regeneration.

Conclusions:

  • MDD devices are increasingly important for precise therapeutic agent application, driven by advances in understanding human biology and disease.
  • The development of multifunctional MDD devices and their use in tissue engineering will expand their medical applications.
  • Continued research into MDD technologies is essential for addressing new therapeutic targets requiring controlled drug presentation.